# Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

> **NCT01804712** · EARLY_PHASE1 · COMPLETED · sponsor: **Christopher Kane** · enrollment: 8 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01804712
- **Lead sponsor:** Christopher Kane
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-08-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804712, "Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01804712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*